NCT03018288 2025-08-08
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
Clinical Trials
6 trialsNCT01814813 2025-01-24
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT01147536 2021-06-03
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
Agenus Inc.
Phase 2 Terminated
NCT00905060 2021-03-24
HeatShock
University of California, San Francisco
Phase 2 Completed
NCT00005628 2013-06-19
Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00098085 2009-03-09
Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
Agenus Inc.
Phase 2 Completed